financetom
Business
financetom
/
Business
/
Walgreens books $5.8-billion impairment charge on VillageMD investment
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Walgreens books $5.8-billion impairment charge on VillageMD investment
Mar 28, 2024 5:12 AM

March 28 (Reuters) - Walgreens Boots Alliance ( WBA )

cut the higher end of its profit forecast for fiscal-year 2024

on Thursday, citing economic headwinds in its retail operations,

and took a $5.8-billion impairment charge related to its

VillageMD business.

VillageMD, which runs doctors' clinics, has been losing

money and burning cash. Walgreens had invested $5.2 billion to

become a majority shareholder in the firm in 2021.

Walgreens has also been grappling with decreased spending on

personal care and beauty products by inflation-weary consumers,

exacerbating the hit from waning demand for its COVID-19

vaccines and testing kits.

The impairment charge dragged the pharmacy operator into a

net loss of $5.9 billion for the quarter ended Feb. 29.

Shares of the company were down 2% at $20.60 in premarket

trading.

On an adjusted basis, Walgreens reported earnings of $1.20

per share for the quarter, compared with analysts' average

estimate of 82 cents per share, according to LSEG data.

The company now expects an adjusted profit of $3.20 to $3.35

per share for its financial year ending Aug. 31, compared to the

$3.20 to $3.50 per share range it gave in January.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cushman & Wakefield, Camden, Blackstone's LivCor Sued by DOJ Over Alleged Rent Pricing Scheme
Cushman & Wakefield, Camden, Blackstone's LivCor Sued by DOJ Over Alleged Rent Pricing Scheme
Jan 7, 2025
02:39 PM EST, 01/07/2025 (MT Newswires) -- Cushman & Wakefield ( CWK ) , Camden Property Trust ( CPT ) , and Blackstone's (BX) LivCor are among the landlords facing a lawsuit filed by the US Department of Justice Tuesday for allegedly participating in an algorithmic pricing scheme. The three landlords along with Greystar Real Estate Partners, Cushman & Wakefield's...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
Jan 7, 2025
(This Dec. 27 story has been corrected to say Opdivo Qvantig has been approved to treat most previously approved tumor indications, not all previously approved tumor indications, in paragraph 5) By Sneha S K and Sriparna Roy (Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster...
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
Jan 7, 2025
Barclays analyst Matt Miksic initiated coverage on Anteris Technologies Global Corp. ( AVR ) with a Positive rating and a forecast of $22. The analyst notes that Anteris Technologies’ DurAVR valve system is expected to become the second balloon-expandable transcatheter valve replacement (BEV TAVR) system by 2028 Clinicians show a clear preference for BEV TAVR systems over self-expanding (SEV) systems...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27)
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27)
Jan 7, 2025
By Sneha S K and Sriparna Roy Dec 27 (Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ( BMY ) blockbuster cancer drug, Opdivo. Opdivo is part of a class of drugs called PD-1 inhibitors, which enhance the immune system's ability to fight cancer by removing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved